Workshop Unites Midwest’s Top Ovarian Cancer Researchers

Nearly 50 scientists gathered at the University of Notre Dame on Sunday and Monday for the Indiana-Illinois End Epithelial Ovarian Cancer Coalition (IIEEOCC) workshop, an effort to advance collaboration and research on a deadly form of cancer that affects over 20,000 women a year.

Colleen, Sharon, Nancy

The workshop, hosted by the Harper Cancer Research Institute, attracted ovarian cancer researchers from nine universities around the Midwest. In poster sessions, presentations, and seminar discussions, researchers discussed topics ranging from new cancer-fighting drugs to the effects of obesity on ovarian cancer development.

“This conference is important because there aren’t that many people in the country who do ovarian cancer research,” said Dr. Sharon Stack, the Ann F. Dunne and Elizabeth Riley Director of the Harper Cancer Research Institute. “We’ve got a lot of really good teams here between Indiana and Illinois and now Wisconsin. It’s a good way to get everybody together and share the different model systems we have. I’m so thankful to the Leo and Anne Albert Charitable Trust for funding this workshop.”

Stack, who spearheaded the inaugural IIEEOCC workshop in 2012, sees the scientific gathering as an ideal way to understand research as it happens. Rather than waiting for peers to publish their work—a process Stack says can take five or six years—researchers can share up-to-date research methods or experimental results with their fellow ovarian cancer researchers.

“We have the whole spectrum of research here,” Stack said. “There are so many important questions. We don’t even know where ovarian cancer comes from. We don’t know how it survives…. We don’t know how to target [cancer cells] or how do deliver therapies. All the presentations are cutting-edge presentations.”

Underlying the workshop’s atmosphere of camaraderie was a collective focus on the need for more research. Ovarian cancer remains a something of a medical enigma: Researchers are still trying to understand its origin point in the body, a way to detect its emergence earlier, and why it spreads so quickly in environments normally hostile to cancer cells.

That lack of understanding makes ovarian cancer particularly deadly. It often goes undetected until it has advanced into late stages. When ovarian cancer does present symptoms, they are often so generic—bloating, loss of appetite, low back pain or indigestion—that afflicted women often dismiss the symptoms as mere digestive problems.

Nancy White and Colleen Olund, both ovarian cancer survivors, talked about the challenges of confronting those symptoms in keynote addresses. White and Olund, who have participated in clinical trials for new treatments, emphasized how research made an impact on their fights against ovarian cancer.

“I’m lucky to be here, because I wouldn’t be here if it weren’t for research and research scientists,” said White, the co-founder and current chair of Gyna Girls, a gynecological cancer survivors’ group dedicated to supporting cancer patients and raising public awareness of ovarian cancer. “I’m hoping with your research that we can figure out more targeted therapies. I’d like to see a test so we can diagnose this early.”

White was first diagnosed with stage 3c ovarian cancer, its most severe form, in 1996. Doctors gave her 18 months to live. But after participating in a specialized research trial at Loyola University Chicago—she was the second woman in the United States to do so—White successfully completed treatments and has since remained cancer-free.

Olund, a participant in Gyna Girls who has struggled with bouts of ovarian cancer since her initial diagnosis in early 2005, emphasized the need for less debilitating treatments.

“Ultimately, we would both like to see the absolute cure for this awful disease,” said Olund, who participated in a clinical trial in which doctors used her own cancer cells to develop an anticancer vaccine. “One thing that would be very important to me, and to other people who tend to battle this over and over again, is something to help manage the side effects of the treatment itself. You could very easily say that the treatment is almost worse than the disease. I lose large parts of my life because of the treatment, as do other women who go through this. Anything that could ameliorate that would be good.”

Dr. Ken Nephew, a professor at the Indiana University School of Medicine who moderated a discussion on Monday afternoon, said he was encouraged by the personal and scientific connections formed at the workshop.

“Nothing beats face-to-face,” Nephew said. “When you get here and you talk to people, it is so valuable. It’s a great opportunity for us to be in the same room and to discuss [research] in some depth. Meaningful collaborations come out of meetings like this.”

Even though the workshop is still in its second year, those collaborations have already borne scientific progress. Nephew and Stack highlighted an article co-authored by attendees of the most recent IIEEOCC workshop, which reviewed different experimental methods in ovarian cancer research. The article was ultimately published in Oncogene, an international scientific journal that will help disseminate the group’s findings to researchers around the world.

“As a result of our coming together last year at this meeting, we formed another collaboration on testing these models in vivo for the community,” Nephew said. “I don’t think that would have happened had we not had really good face-to-face interactions here.”

For White, the workshop was a promising symbol of partnership.

“I can’t tell you how lucky we are that Harper is here,” she said. “We need to get the word out about this deadly disease. This is amazing that we can have a conference about this.”